The WHO standardisation helps in the regulation of Covid-19 virus serological methods and allows for cross-lab data comparison. The new assay is designed to detect IgG antibodies to SARS-CoV-2 in human serum and plasma in a qualitative and quantitative manner. The test would make it easier to determine a person’s immune response after being infected with the SARS-CoV-2 virus or having a vaccine.
It will be used as a standardised method for public health staff to measure improvements in Covid-19 patients’ antibody levels and monitor the disease’s spread. Chockalingam Palaniappan, the Ortho Clinical Diagnostics chief innovation officer, said, “Ortho’s new quantitative IgG antibody test provides healthcare teams and researchers with a standardised data ‘ruler,’ to assess immune response, acquired through infection or from vaccines, over time, offering additional data to help manage and understand this devastating virus.”
The VITROS Anti-SARS-CoV-2 IgG Quantitative test is a recent addition to Ortho’s Coronovirus portfolio, and it can be used to diagnose and treat coronavirus infections as well as monitor people’s immune responses. The new VITROS Anti-SARS-CoV-2 IgG Quantitative (QN) Antibody assay from Ortho Clinical Diagnostics has gained CE certification, indicating that it meets the World Health Organization (WHO) International Standard.